Texas cancer diagnostics company Castle Biosciences plans to expand the clinical availability of its tests that assess “rare and underserved cancers,” particularly one for cutaneous melanoma. It has wrapped up an $11.8 million round to do so, the company said.
The round was led by new investor HealthQuest Capital; existing investors Mountain Group Capital and Affiliates, Longfellow Venture Partners and others also joined the round.
The company has a portfolio of genomics-based tests lined up for cutaneous melanoma, uveal melanoma, esophageal cancer, thymic cancers, mesothelioma and gliomas. Each of these fit the orphan cancer criteria, Castle Biosciences says, meaning they present a first-to-market opportunity for the company.